2.1 Corporate social responsibility (CSR)
PCI Biotech is a Norwegian based company focusing on development and commercialisation of novel
therapies and new technologies through its innovative photochemical technology platform. The PCI
Biotech Group consists of 7 employees and the core competencies are possessed by these
employees, while the group's other resources in research and development are mainly purchased
from public and private research institutions and service providers across Europe and USA.
As of today, the Group has no sales or supply of services and a limited complexity in operations. The
Group has established guidelines and policies in accordance with internal control policies for
comparable businesses of similar size, complexity, and industry to fight corruption. This means that
the group requires its directors and employees to demonstrate high ethical standards in business and
interpersonal relationships. Other principles followed are prevention through awareness-raising,
limitation of opportunities, high detection risk of, and zero tolerance for corruption.
The Group has established its own quality control system in line with authorities’ requirements within
the activities that the Group operates, in terms of production and storage of pharmaceutical products.
The quality control procedures are based on the relevant activities in relation to the different phases of
operation and the development of procedures is thus a dynamic process. The Group is concerned that
staff have appropriate training and experience in their business areas and staff are regularly updated
within their business fields.
The Group is concerned with animal welfare, human- and labour rights, social issues, and sustainable
development. The Group's management conducts regular performance reviews and internal
evaluations, and the Group adapts according to Norwegian law within the area. Preclinical research is
subject to strict government regulation on animal welfare. The Group considers that animal welfare,
human rights, labour rights, and social issues are well taken care of, both internally and among its
subcontractors. Regarding sustainable development, please see section 2.2.
The Group has not identified any material issues based on the corporate social responsibility
procedures (CSR) performed in 2023. The implementation of further detailed specific objectives,
strategies or action plans related to CSR, beyond the ones described above, has not yet been
prioritised, but will be developed along with the continuous development of PCI Biotech’s operations.
Non-conformance with the recommendation: The Group's operations are of such character that it does
not significantly affect the environment and the Group therefore believes it is not appropriate to
establish specific guidelines, policies, procedures and standards in this area, but environmental issues
are included in PCI Biotech’s ethical guidelines and please also see the separate reporting regarding
sustainable development in section 2.2.
2.2 Sustainable development
PCI Biotech is concerned with sustainability, but has not used any specific reporting standards or
guidelines for sustainability reporting other than the Code and this section for sustainable development
is considered an integrated part of the CSR reporting. In general PCI Biotech’s strategy and
operations are focused on human welfare through its vision of ‘unlocking the potential of innovative
products and medicines’. PCI Biotech focuses its development on anti-cancer product- and technology
candidates. This vision and focus may directly contribute to one of the UN’s seventeen sustainable
development goals, goal #3 ‘Good health and well-being’. All international anti-cancer development is
strictly regulated regarding animal welfare. PCI Biotech have internal routines securing that the Group
and service providers comply with all relevant standard in these regards.
The Group's operations are of such character that they do not significantly affect the environment
beyond normal course of business for a small biotech company, nevertheless the Company strives to
minimise our environmental footprint in daily operations. Travelling and the need for shipment of
devices and materials for preclinical experiments are identified as the activities with the most
environmental impact. To keep the environmental impact to a minimum, shipments are optimised in
collaboration with our service providers and collaborators to reduce the number of shipments. External
PCI Biotech Holding ASA, Ullernchausséen 64, 0379 Oslo, Norway, Company no: 991036393 VAT
Phone: + 47 67 11 54 00, www.pcibiotech.com
14
